Sensex Today | Stock Market LIVE Updates | Marksans Pharma Q4 Results





Operating revenue was Rs. 560.0 Cr., up by 15.2% YoY driven by by volume gains, new launches, addition of new customers, and increase in our share with existing customers

Gross profit was Rs. 290.2 Cr., up by 19.8% YoY with a Gross margin of 51.8%

EBITDA was Rs. 109.6 Cr., grew by 0.1% with an EBITDA margin of 19.6%

EPS was at Rs. 1.73


Comments